ReNeuron touts new data for peripheral arterial disease

ReNeuron is touting new preclinical data backing the efficacy of its lead CTX stem cell line for peripheral arterial disease.

According to researchers, the stem cells generated "significant recovery of blood flow" in the ischaemic limb. And they hope to graduate to a clinical program in the next two years. The data is being reviewed this week in Oxford, England. In the meantime, ReNeuron is planning an initial clinical trial of the CTX stem cell line this year for disabled stroke victims.

"The results of this study further demonstrate the potency of our lead CTX stem cell line when applied in ischaemic disease settings," says CSO John Sinden. "We are excited by the apparent utility of this cell line in both the ischaemic brain and muscle. The CTX cell line is extremely well-characterized and has already been scaled up and extensively tested as part of our ReN001 program for stroke. This work will therefore give us a significant advantage as we look to move this cell line forward to the clinic as a non-patient-specific therapeutic candidate for peripheral arterial disease."

- read the ReNeuron release

Related Articles:
ReNeuron to recruit stroke victims for stem cell trial
ReNeuron looks beyond U.S. for trial approval (Mar 2008)
ReNeuron looks to resolve FDA issues (Feb 2008)